INHIBITING IRON METABOLISM TO TARGET METASTASES

A Data Management Plan created using DMPonline.be

Creator: Prof. Sarah-Maria Fendt / Tine Tricot

Affiliation: KU Leuven (KUL)

Funder: KU Leuven (KUL)

Template: KU Leuven BOF-IOF

Grant number / URL: C14/22/137

ID: 196718

Start date: 01-10-2022

End date: 30-09-2026

Project abstract:

Metastasis formation is the leading cause of death in cancer patients. Unfortunately, we have currently no effective treatment against metastases. The effect of this lack of treatment options is dramatically illustrated in the case of breast cancer resulting in over 685 000 deaths per year. Thus, there is an urgent need for novel therapeutic options against a metastatic disease. We have discovered that the tumors of metastatic breast cancer patients show a gene expression signature indicative of iron metabolism and that targeting iron metabolism in mouse models prevents metastasis formation. Thus, we will i) dissect how iron metabolism aids metastases, ii) define the therapeutic potential of targeting iron metabolism and iii) translate this therapeutic potential beyond breast cancer. In conclusion, we will deliver a mechanistic understanding of iron metabolism resulting in novel therapeutic strategies against established metastases. We expect that on the long-term our findings will benefit cancer patients.

Last modified: 09-03-2023

INHIBITING IRON METABOLISM TO TARGET METASTASES

RESEARCH DATA SUMMARY

List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data.

| Dataset name / ID | Description | New or reuse | Digital or Physical data | Data Type | File format | Data volume | Physical volume |
|-------------------|-------------|---|------------------------------------|---|-------------|---|-----------------|
| | | Indicat e: N(ew data) or E(xisti ng data) | Indicate: D (igital) or P(hysical) | Indicate: Audiovisual Images Sound Numerical Textual Model SOftware Other (specify) | | Indicate: <1GB <100GB <1TB <5TB >5TB NA | |

| Microscopy images of cell cultures and images of cell cultures and images of cell cultures and immunohistochem istry Inventory files Inventory files containing detailed information about cell lines, chemicals, oligonucleotides, plasmids, lentiviral vectors, pseudorymized human samples and their storage location Digital Images of mouse this suser/metastasis as will be taken with a digital camera of H&E stainings of primary tumor and stainings of primary tumor and many sistems, respectively. RT-qPCR Gene expression analysis from collabrisation colorometric assays Western Protein quantification (Quantification) colorometric assays kits and plate reader assays will be measured using the Camer of control and sockout breast cancer cells will be assessed invitor using the Seatorse XF analyzer. Mass spectrometry plasms asmples will be measured using the CaMS and LC-MS systems, resulting and LC-MS systems, | | T | | _ | Γ. | | | |
|--|-----------------|--------------------|-------|----------|-----------|-------------|--------|---|
| Inventory files Inventory | | | N | D | 1 | .jpg/.tiff | <100GB | / |
| Inventory files containing detailed information about cell lines, chamicals, lending detailed information about cell lines, colligorucleoides, plasmids, lentiviral vectors, pseudorymized human samples and their storage location Digital betaken with a digital camera lines of mouse of H3E stainings of primary tumor and lung metastasis will be analyzed using the CuPath software RT-qPCR Gene expression analysis from collishissue using Quantification/ Quantification using BCA or colorometric assays kits and plate reader assays wits and plate reader seahorse x x analyzer. Mass Tissue and plasma smaples and the C-MS D SO/N x/dxx x/dx/x/dx x/dx/x/dx/x/dx/dx/x/dx/ | images | | | | | | | |
| Inventory files Inventory files on Inventory files | | | | | | | | |
| containing detailed information about cell lines, chemicals, oligonucleotides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location lines will be taken with a digital camera High quality seans of H&E stainings of primary tumor and lung metastasis stainings of primary tumor and lung metastasis stainings at signing the QuPath software Quantification Protein Quantification using BCA or colorometric assays with a measurement s and plate reader assessed invitro using the Quayer. Mass Tissue and spectrometry of the part of the protein of the part of the plate and plasma samples will be assessed invitro using the Qu-Path spectrometry of the part of the protein of the part of the | | | | | | | | |
| detailed information about cell lines, chemicals, clemicals, clemicals, clemicals, clemicals, soligonuclectides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location Digital photographs Images of mouse stassue/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/tissues using Quant/Studio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification/ Quantification using BCA or colorometric assays RT-qpCR The oxygen consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and spectrometry Tissue and plasma samples and their storage information and plasma samples will be measured using the GC-MS and LC-MS an | Inventory files | Inventory files | N | D | Т | .xlsx | <1GB | / |
| information about cell lines, chemicals, oligonucleotides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location Digital Images of mouse tissues/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuParth software RT-qPCR Gene expression analysis from celloritissues using the Quantification/ expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays Colorometric assays Tissue and plasma samples and the protein of the consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples and the cell will be assessed using the CL-MS and LC-MS and LC | | | | | | | | |
| cell lines, chemicals, chemicals, clamicals, clamicals, soligonucleotides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location Digital photographs Images of mouse issues/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/tissues using Quant/Studio3 Western blotting Protein quantification/ color imager and ImageQuant software Protein quantification or using BCA or colorometric assays RT-qpCR The coxygen consumption measurement of plate reader sassays Protein quantification or consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS and LC-M | | | | | | | | |
| chemicals, oligonucleotides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location Digital Images of mouse tissues/metastasis swill be taken with a digital camera of H8E stainings of Drimary tumor and lung metastasis Analysis H8E High quality scans of H8E stainings of Drimary tumor and lung metastasis Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification/ plate reader assays Protein Quantification/ plate reader assays Oxygen Consumption measurement of plate reader assays with an plate reader assays with a seasessed invitro using BCA or consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS and LC-MS and LC-MS and the consumption measurement or spectrometry and plasma samples will be measured using the GC-MS and LC-MS a | | | | | | | | |
| oligonucleotides, plasmids, lentiviral vectors, pseudonymized human samples and their storage location photographs Images of mouse sissues/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden lung metastasis Analysis H&E Gene expression analysis from cells/fitsuse using QuantStudio3 Western Protein Protein expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification/ quantification/ quantification/ plate reader Protein consumption measurement of consumption receils will be assessed invitro using BCA or consumption reasurement software assays kits and plate reader Mass Tissue and N D SO/N Image and N D SO/N Image and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/IT Imas/d/ SGB / Image and plasma samples will be measured using the GC-MS and LC-MS Image and L | | • | | | | | | |
| plasmids, lentiviral vectors, pseudonymized human samples and their storage location Digital Images of mouse tissues/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression N analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays kits and plate reader Protein quantification for consumption rate of consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/IT .ms/.d/ SGB / .ms/.d/ .ms/.d/ .ms/.d/ .ms/.png /.pdf Mess and LC-MS SO/N/IT .ms/.d/ .ms/.png /.pdf | | | | | | | | |
| pseudonymized human samples and their storage location Digital Images of mouse tissues/metastasis swill be taken with a digital camera H&E H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/fissues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification using BCA or consumption measurement of control and knockout breast cancer cells will be assessed invitro using the Seahorse x X analyzer. Mass Tissue and plasma samples will be measured using the CL-MS and LC-MS and LC-MS and their storage in the consumption and plasma samples will be measured using the CL-MS and LC-MS and LC-M | | | | | | | | |
| human samples and their storage location Digital Images of mouse tissues/metastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/fitssues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification using BCA or colorometric assays Oxygen consumption measurement of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/IT .ms/d/ 5GB / .mat/png /.pdf In Jpg 5GB / .mat/png /.pdf | | | | | | | | |
| and their storage location Digital photographs Images of mouse tissues/inetastasis swill be taken with a digital camera H&E High quality scans of H&E stainings of H&E stainings of primary tumor and lung metastasis Analysis H&E staining will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/itissues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ using BCA or colorometric assays Dxygen consumption measurement of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/NVI/T .ms/d/ .mat/png /.pdf In Jipg 5GB / .ms/d/ .ms/d/ .ms/d/ .mat/png /.pdf Jipg 5GB / .ms/d/ .ms/d/ .ms/d/ .ms/d/ .mat/png /.pdf | | | | | | | | |
| Illocation | | | | | | | | |
| Digital photographs Images of mouse tissues/metastasis swill be taken with a digital camera | | | | | | | | |
| photographs tissues/metastasis s will be taken with a digital camera N D I .qptiff <100GB / | Digital | | N | D | 1 | .ipa | 5GB | / |
| H&E High quality scans of H&E stainings of primary tumor and lung metastasis Analysis H&E Metastatic burden will be analyzed using the QuPath software QuantStudio3 Western Protein expression analysis using the LAS4000 imager and lmageQuant software Protein quantification/ quantification/ quantification/ colorometric assays Oxygen consumption measurement s cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plate reader asspectrometry Mass Tissue and plate measured using the GC-MS and LC-MS In Insue and LC-MS Insue A Insue, and | | | | | | " 3 | | |
| H&E stainings of H&E stainings of primary tumor and lung metastasis Analysis H&E staining will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/tissues using QuantStudio3 Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification using BCA or colorometric assays Oxygen consumption consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS IN D SO/N III (ppd) (pp | | | | | | | | |
| Stainings of H&E stainings of primary tumor and lung metastasis Analysis H&E staining will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/sissues using QuantStudio3 Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays Oxygen consumption rate of control and knockout breast cancer cells will be assessed invitor using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS IN D SO/N IXISX S | | | | | | | 10000 | , |
| of primary tumor and lung metastasis Analysis H&E Staining Metastatic burden will be analyzed using the QuPath software RT-qPCR Gene expression analysis from cells/tissues using Quantstudio3 Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ Quantification using BCA or colorometric assays kits and plate reader assays with the consumption measurement softwore will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS | | | N | ט | 1 | .qptiff | <100GB | / |
| and lung metastasis Analysis H&E staining Analysis Western blotting Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ colorometric assays (Colorometric assays) Oxygen consumption measurement software Analysis and plate reader Analysis and plate reader Analysis using the sassessed invitro using the Seahorse XF analyzer. Mass pectrometry Analysis Analysis and plate measured using the GC-MS and LC-MS Analysis Analyzer. Analysis Analyzer and ImageAuant software Analysis Analyzer and ImageAuant software Analysis Analyzer and N D SO/N Analysis Alisx Alisx Alisx Alight analyzer. Analyzer and ImageAuant software and plate reader assays kits and plate reader assays kits and plate reader assays analyzer. Analyzer analyzer and plasma samples will be measured using the GC-MS and LC-MS | Stairings | | | | | | | |
| Analysis H&E staining | | | | | | | | |
| staining will be analyzed using the QuPath software RT-qPCR | | | | | | | | |
| using the QuPath software RT-qPCR Gene expression analysis from cells/tissues using QuantStudio3 Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ using BCA or colorometric assays kits and plate reader assays Noxygen consumption measurement software The oxygen consumption measurement seasons and location and | | | N | D | SO/N | .xlsx | <1GB | / |
| RT-qPCR Gene expression analysis from cells/tissues using QuantStudio3 Western blotting Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ colorometric assays kits and plate reader of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Spectrometry Mass Spectrometry RT-qPCR Gene expression N D D SO/N .xlsx <1GB / .pg SO/I .gel/.tiff/ 5GB / .pg SO/IN .xlsx <1GB / .pg SO/IN .xlsx <1GB / .pg SO/IN .xlsx <1GB / .pg Analysis using the SO/IN .xfd/.xlsx <10GB / .pg SO/IN .xlsx <10GB / .pg SO/IN .xlsx / .pg SO/IN | staining | | | | | | | |
| RT-qPCR Gene expression analysis from cells/tissues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ quantification/ quantification/ software Posterin expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ using BCA or colorometric assays kits and plate reader assays Oxygen consumption consumption consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS D SO/N .xlsx <1GB / SO/N .xfd/.xlsx <10GB / SO/N .xfd/.xlsx / SO/N .x | | | | | | | | |
| analysis from cells/tissues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays Oxygen Consumption measurement S Mass Tissue and Spectrometry Mass Tissue and Spectrometry Mass Spectrometry The Tissue and Spectrometry Analyzer. N D SO/I .gel/.tiff/ 5GB / SO/I .stlsx <1GB / SO/IN .xlsx <1GB / SO/IN .xfd/.xlsx <10GB / SO/IN .xlsx / SO/IN .xfd/.xlsx / SO/IN .xlsx / SO/IN | RT-aPCR | | N | D | SO/N | vlev | ∠1GB | / |
| Cells/tissues using QuantStudio3 Western Protein expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ using BCA or colorometric assays kits and plate reader Oxygen Consumption measurement s Mass Tissue and spectrometry Mass Tissue and Spectrometry Mass Tissue and Spectrometry Cells/tissues using QuantStudio3 N D SO/N .xlsx <1GB / SO/N .xlsx <1GB / SO/N .xfd/.xlsx <10GB / SO/N .xfd/.xlsx / SO/N .xlsx / SO/N .x | I KI GI OK | | ' | | 00/14 | .XIOX | 100 | , |
| Protein expression analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays kits and plate reader Protein Quantification of consumption measurement s Protein Quantification Protei | | | | | | | | |
| blotting expression analysis using the LAS4000 imager and ImageQuant software Protein quantification/ using BCA or colorometric assays kits and plate reader Oxygen consumption measurement s Mass spectrometry Mass spectrometry D SO/N .xlsx <1GB / SO/N .xlsx <1GB / SO/N .xfd/.xlsx <10GB / SO/N .xfd/.xlsx / | | | | | | | | |
| analysis using the LAS4000 imager and ImageQuant software Protein Quantification using BCA or colorometric assays Oxygen The oxygen consumption measurement s Oxygen consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and spectrometry place and spectrometry service and ser | | | N | D | SO/I | .gel/.tiff/ | 5GB | / |
| LAS4000 imager and ImageQuant software Protein Quantification Using BCA or colorometric assays kits and plate reader Oxygen consumption measurement S Mass Spectrometry Protein Quantification Using the Seahorse XF analyzer. Mass Spectrometry Spectro | blotting | | | | | | | |
| Protein quantification value of colorometric assays Oxygen consumption measurement s N D SO/N SO/N SO/N SO/N SISX SO/N SISX SO/N SISX SO/N SISX SO/N SO/ | | LAS4000 imager | | | | ing | | |
| Protein quantification/ using BCA or colorometric assays kits and plate reader Oxygen consumption measurement s Mass Spectrometry Mass Spectrometry Software Quantification N | | | | | | פאני | | |
| quantification/ using BCA or colorometric assays kits and plate reader Solvygen consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and spectrometry plasma samples will be measured using the GC-MS and LC-MS | | software | | | | | | |
| colorometric assays kits and plate reader Solvygen consumption measurement s knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass spectrometry Mass will be measured using the GC-MS and LC-MS | | | N | D | SO/N | .xlsx | <1GB | / |
| colorometric assays Oxygen | quantification/ | | | | | | | |
| colorometric assays Oxygen | | | | | | | | |
| Oxygen consumption measurement s Mass spectrometry Mass and LC-MS Oxygen consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. D SO/N .xfd/.xlsx <10GB / SO/N .xfd/.xlsx / SO/N .xfd/.xlsx <10GB / SO/N .xfd/.xlsx / S | colorometric | | | | | | | |
| Oxygen consumption rate of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass spectrometry Mass spec | | , | | | | | | |
| measurement s of control and knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass spectrometry Plasma samples will be measured using the GC-MS and LC-MS Plasma samples will be measured using the GC-MS and LC-MS Plasma samples will be measured using the GC-MS and LC-MS Plasma samples will be measured using the GC-MS and LC-MS Plasma samples will be measured using the GC-MS and LC-MS Plasma samples will be measured using the GC-MS plasma samples will be measured using | Oxygen | | N | D | SO/N | .xfd/.xlsx | <10GB | / |
| s knockout breast cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and plasma samples will be measured using the GC-MS and LC-MS Knockout breast cancer cells will be assessed by invitro using the Seahorse XF analyzer. So/N/I/T .ms/.d/ .ms/.d/ .xlsx/.m/ .mat/.png /.pdf | | | | | | | | |
| cancer cells will be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/I/T .ms/.d/ .ms/.d/ .xlsx/.m/ .mat/.png /.pdf /.pdf | | | | | | | | |
| be assessed invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/I/T .ms/.d/ .xlsx/.m/ .mat/.png /.pdf /.pdf | ٥ | | | | | | | |
| invitro using the Seahorse XF analyzer. Mass Tissue and N D SO/N/I/T .ms/.d/ .xlsx/.m/ .mat/.png /.pdf /.pdf /.pdf | | | | | | | | |
| Mass spectrometry Tissue and plasma samples will be measured using the GC-MS and LC-MS D SO/N/I/T .ms/.d/ .ms/.d/ .xlsx/.m/ .mat/.png /.pdf 5GB / .xlsx/.m/ .mat/.png /.pdf | | invitro using the | | | | | | |
| Mass spectrometry Plasma samples will be measured using the GC-MS and LC-MS D SO/N/I/T .ms/.d/ .xlsx/.m/ .mat/.png /.pdf // .pdf // .pdf | | | | | | | | |
| spectrometry plasma samples will be measured using the GC-MS and LC-MS .xlsx/.m/ .mat/.png /.pdf | Moos | | NI NI | <u> </u> | CO/N///T | mo/ d/ | ECD | 1 |
| will be measured using the GC-MS and LC-MS .mat/.png /.pdf | | | IN . | ט ן | 5U/N/I/ I | | SGR | / |
| using the GC-MS /.pdf and LC-MS | Specifornelly | | | | | | | |
| and LC-MS | | | | | | | | |
| systems, resulting | | and LC-MS | | | | | | |
| | | systems, resulting | | | <u> </u> | <u> </u> | | |

| | T | | Т | 1 | ı | Т | <u> </u> |
|------------|--|----|---|-----------|-------------|-------|----------|
| | in the generation | | | | | | |
| | of raw data files | | | | | | |
| | (.ms and .d files, | | | | | | |
| | respectively). | | | | | | |
| | The .ms and .d | | | | | | |
| | files will be | | | | | | |
| | integrated using | | | | | | |
| | the Agilent | | | | | | |
| | ChemStation | | | | | | |
| | (compatible with | | | | | | |
| | the .ms files) and Agilent | | | | | | |
| | MassHunter | | | | | | |
| | software | | | | | | |
| | (compatible with | | | | | | |
| | the .d files). The | | | | | | |
| | integrated data | | | | | | |
| | will subsequently | | | | | | |
| | be exported as | | | | | | |
| | excel files (.xlsx) | | | | | | |
| | and further | | | | | | |
| | analyzed in | | | | | | |
| | MATLAB, leading | | | | | | |
| | to the generation | | | | | | |
| | of data analysis | | | | | | |
| | scripts (.m) and | | | | | | |
| | data files (.mat). | | | | | | |
| | The output of the | | | | | | |
| | data analysis will | | | | | | |
| | be exported in | | | | | | |
| | excel files (.xlsx) | | | | | | |
| | and figure files | | | | | | |
| chIP/RNA | (.png or .pdf). Sequencing data | N | D | SO/N/I/T | .fastq/.mtx | 100GB | / |
| sequencing | file (.fastq), count | IN | | 30/11/1/1 | /.bam/.R/ | 10000 | , |
| Sequenting | matrix (.mtx) and | | | | .Rdata/.txt | | |
| | genome-aligned | | | | /.gmt/.rnk | | |
| | (.bam) files will be | | | | /.narrowPea | | |
| | generated. Data | | | | k | | |
| | analysis will be | | | | /.BroadPeak | | |
| | conducted in R, | | | | /.bedGraph/ | | |
| | generating R | | | | .tdf/.html/ | | |
| | script files (.R) | | | | .xlsx/.png | | |
| | with analysis | | | | | | |
| | output (.RData, | | | | | | |
| | and .txt). Gene set | | | | | | |
| | enrichment | | | | | | |
| | analysis (GSEA) | | | | | | |
| | will be conducted, | | | | | | |
| | requiring libraries | | | | | | |
| | of pathways (.gmt) | | | | | | |
| | and normalized | | | | | | |
| | transcriptome | | | | | | |
| | reads in a ranked format (.rnk). | | | | | | |
| | Peak Calling will | | | | | | |
| | be performed for | | | | | | |
| | chIP sequencing | | | | | | |
| | Jan Jaguarianig | | | | | | |
| | analysis to identify | | | | | | |
| | analysis to identify the regions which | | | | | | |
| | the regions which | | | | | | |
| | | | | | | | |

| | T | 1 | l . | 1 | 1 | 1 | |
|------------------------------------|---|-----|-----|--------|----------------------------|------|---|
| | consequence of protein binding, leading to the generation of .narrowPeak or .broadPeak files. The data will be will visualized in .bedGraph and .tdf files. Output files are produced in various formats (.html, .xlsx, .png images). | | | | | | |
| Bioluminesce nce | Bioluminescence imaging will be performed to measure the luciferin flux using the IVIS Spectrum system. Bioluminescence will be analyzed using the LivingImage processing software. | N | D | SO/N/I | .txt/.xlsx/ .tiff/.jpg | <1GB | |
| Statistical and graphical analysis | GraphPad Prism9 will be used for all statistical analyses and graphical designs | N | D | SO/I | .pdf/ .png/ . wmf/ .svg | 5GB | / |
| Electronic lab book | Experimental and computational protocols, as well as details related to collection and processing of data (both documentation and metadata) will be stored on the electronic lab book platform Benchling | N | D | Т | .pdf | <1GB | |
| Cell lines | Cell lines will be stored in liquid nitrogen tanks | N/E | Р | / | / | / | 1-2 box for 81 samples |
| Plasmids | Plasmids will be stored in -20 degrees freezer | N/E | Р | / | / | / | 1 storage box for eppendor f tubes |
| Viral vectors | Viral vectors will be stored in -80 degrees freezer | N | Р | / | / | / | 1 storage box for eppendor f tubes |
| Human samples | Interstitial fluid of multiple metastatic organs as well as metastatic tissue | N/E | P | / | / | / | 3 full racks in - 80 freezer (48 |

| of multiple organs will be stored in - 80 degrees | | | storage boxes) |
|---|--|--|-------------------|
| freezer | | | |

If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type:

Not applicable, we will reuse research material to generate new data.

Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.

- Yes, human subject data (Provide SMEC or EC approval number below)
- Yes, animal data (Provide ECD reference number below)

Clinical data from patients will be accessed through the UZ Leuven (Prof. Wildiers) biobanks and will only contain information on the age of the patient, initials and a personal identification number as well as health data (e.g. description of characteristics of physical features of the body, medical history and medical test information (such as blood samples results from scans and biopsies)). GDPR approval was obtained before applying for ethical approval at the KU/UZ Leuven EC by Prof. Wildiers. The approval is available and outlined in EC S63773 and S64410.

Animal experiments will be performed during this project. All experiments have been approved by the Ethical Committee for Animal Experimentation (ECD) at KU Leuven and are available and outlined in ECD #P145-2019, #P021-2022, #P022-2022.

Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).

Yes (Provide PRET G-number or EC S-number below)

Clinical data from patients will be accessed through the UZ Leuven (Prof. Wildiers) biobanks and will only contain information on the age of the patient, initials and a personal identification number as well as health data (e.g. description of characteristics of physical features of the body, medical history and medical test information (such as blood samples results from scans and biopsies)). GDPR approval was obtained before applying for ethical approval at the UZ Leuven EC by Prof. Wildiers (\$63773 and \$64410).

Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, ...)? If so, please comment per dataset or data type where appropriate.

Yes

Intellectual Property arising from this work is managed as per the framework agreement between the VIB (VIB Tech Transfer) and the KU Leuven, the two participating institutes in this study.

Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer agreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what restrictions are in place.

Yes

Yes, as above, dissemination or exploitation of the data is managed according to the framework agreement between the VIB and the KU Leuven.

Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted.

Yes

Intellectual Property arising from this work is managed as per the framework agreement between the VIB (VIB Tech Transfer) and the KU Leuven.

DOCUMENTATION AND METADATA

Clearly describe what approach will be followed to capture the accompanying information necessary to keep data understandable and usable, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded).

Protocols and details related to data collection and processing will be recorded in electronic lab books by the lead post-doctoral scientist (Dr. Sara Isabel Fernandes) and lab technician (Gabriella Dow). Data folders containing raw and processed data will be hierarchically organized and labeled based on the source of the data, the type of experiment, the date of data generation, and the different experimental conditions analyzed. Data analysis methods and particularities (including metadata) will be described in README.txt and Excel files included in these folders. All files will be stored in the KU Leuven Large Volume Storage space (L-Drive), with sharing possibilities via One Drive (managed by the KU Leuven IT department).

Will a metadata standard be used to make it easier to find and reuse the data? If so, please specify which metadata standard will be used.

If not, please specify which metadata will be created to make the data easier to find and reuse.

No

Text documents and Excel files stored within each experiment folder in the L-Drive will contain guidelines describing data collection/analysis methods and all relevant metadata (including experimental conditions, sample keys, computational analysis pipelines and their parameters) to ensure the reusability of the data and the reproducibility of any further data generation.

DATA STORAGE & BACK-UP DURING THE RESEARCH PROJECT

Where will the data be stored?

- Large Volume Storage
- OneDrive (KU Leuven)

Upon data collection/preprocessing, temporary copies of the data will primarily be stored in the KU Leuven-managed personal OneDrive account of the lead post-doctoral scientist (Dr. Sara Isabel Fernandes) and lab technician (Gabriella Dow). A copy of the data will be immediately uploaded to the KU Leuven Large Volume Storage space (L-Drive) for long-term preservation and backup.

How will the data be backed up?

Standard back-up provided by KU Leuven ICTS for my storage solution

Data stored on the KU Leuven L-Drive is managed, maintained, and backed up by KU Leuven IT services.

Is there currently sufficient storage & backup capacity during the project?

If no or insufficient storage or backup capacities are available, explain how this will be taken care of.

Yes

The KU Leuven L-drive has sufficient storage capacity for the outlined project.

How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?

Data stored intermediately on personal KU Leuven OneDrive accounts that are protected via password access set up by KU Leuven IT. Off-site access to L-drive data is available by KU Leuven data access points and is password protected. Access to modify these files are limited to lab members with access to the Fendt Lab L-Drive folders.

What are the expected costs for data storage and backup during the research project? How will these costs be covered?

The annual cost of KU Leuven L-Drive storage is 569.2 euro/5TB/year. This cost and capacity include the performance of mirror copies of the stored data, for safety backup purposes. We expect that 5TB will be sufficient to store all data generated as part of the project. These costs will be covered by the budget of the project lead (Prof. Sarah-Maria Fendt).

DATA PRESERVATION AFTER THE END OF THE RESEARCH PROJECT

Which data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of the project?

In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...).

All data will be preserved for 10 years according to KU Leuven RDM policy

Where will these data be archived (stored and curated for the long-term)?

Large Volume Storage (longterm for large volumes)

What are the expected costs for data preservation during the expected retention period? How will these costs be covered?

The annual cost of L-Drive storage is 569.2 € per 5TB of storage space per year. We expect that 5 TB will be sufficient for long-term storage of all data generated as part of the project. These costs will be covered by the budget of the project lead (Prof. Sarah-Maria Fendt).

DATA SHARING AND REUSE

Will the data (or part of the data) be made available for reuse after/during the project? Please explain per dataset or data type which data will be made available.

- Yes, as open data
- Yes, as restricted data (upon approval, or institutional access only)

We will use tumor samples collected from patients at UZ Leuven. Therefore, we have a Material and Data Transfer Agreement (MTA) between the legal entities of KU Leuven/UZ Leuven and VIB in place. These 3rd party agreements will not restrict dissemination of the data that will be generated within this project. The results of this project will be communicated in established, peer-reviewed (non-predatory) academic journals, that require disclosure of all included data. Patient data will therefore be made available in restricted access repositories. Requests for access to the patient data will be assessed on a case-by-case basis by the Data Access Committee, KU/UZ Leuven and the project lead (Prof. Sarah-Maria Fendt). Personal data will only be published after deidentification to protect the identity of the patients. The identifiers will not be published. In order to protect the privacy of the patients, their tumor samples will only be made available to lab members involved in the project, not to other groups or studies unless ethical approval has been obtained.

All sequencing data generated from non-patient material will be made available on the open access repository, GEO. Other data will be shared externally upon request of collaborating scientist, which will be reviewed and approved on case-by-case basis by Prof. Fendt.

If access is restricted, please specify who will be able to access the data and under what conditions.

Patient data will be made available in restricted access repositories. Requests for access to the patient data will be assessed on a case-by-case basis by the Data Access Committee, KU/UZ Leuven and the project lead (Prof. Sarah-Maria Fendt).

Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)?

Please explain per dataset or data type where appropriate.

- Yes, intellectual property rights
- Yes, ethical aspects

Intellectual Property arising from this work is managed as per the framework agreement between the VIB (VIB Tech Transfer) and the KU Leuven, the two participating institutes in this study.

Patient data will be made available in restricted access repositories. Requests for access to the patient data will be assessed on a case-by-case basis by the Data Access Committee, KU/UZ Leuven and the project lead (Prof. Sarah-Maria Fendt).

Where will the data be made available?

If already known, please provide a repository per dataset or data type.

Other data repository (specify below)

All sequencing data generated from non-patient material will be made available on the open access repository, GEO. Patient data will be made available in restricted access repositories (sequencing data in EGA and imaging data in OMERO).

When will the data be made available?

• Upon publication of research results

Which data usage licenses are you going to provide?

If none, please explain why.

Data Transfer Agreement (restricted data)

Do you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please provide it here.

• Yes, a PID will be added upon deposit in a data repository

What are the expected costs for data sharing? How will these costs be covered?

Costs for data sharing will be discussed with collaborators on a case-by-case basis. To minimize data management costs, free-to-use data repositories will be used when possible. Data management will be covered by own funding.

RESPONSIBILITIES

Who will manage data documentation and metadata during the research project?

Prof. Sarah-Maria Fendt accepts all responsibility for data documentation and metadata. Dr. Sara Isabel Fernandes and Gabriella Dow will be responsible for experimental data. Dr. Margarida Campos (mass spectrometry specialist) will be responsible for mass spectrometry data.

Who will manage data storage and backup during the research project?

The lead postdoctoral scientist (Dr. Sarah Isabel Fernandes) and lab technician (Gabriella Dow) will be primarily responsible for collecting/generating data, and for correct documentation and upload onto the L-Drive storage space. The KU Leuven IT department will be responsible for maintenance and back up of the L-Drive data storage space.

Who will manage data preservation and sharing?

Prof. Sarah-Maria Fendt will be responsible for ensuring data preservation, sharing and reuse.

Who will update and implement this DMP?

Prof. Sarah-Maria Fendt bears the end responsibility of updating & implementing this DMP.